Anti-Obesity Medication Market Size to be USD 105.3 Billion by 2035; Surging Obesity Cases to Fuel Market Growth

Anti-obesity medication, also known as weight loss medications, are pharmacological agents that reduce or control excess body fat. Target market is driven by the increasing cases of obesity, rising awareness of the health consequences associated with being overweight. In addition, rising R&D activities for development of anti-obesity drugs, and increasing investment in R&D sectors are another factors propelling growth of the global market.

Anti-Obesity Medication Market Segmentation Analysis:

By Drug Type	Prescription Drugs and Over-the-Counter (OTC) Drugs
By Mechanism of Action	Centrally Acting Drugs and Peripherally Action Drugs
By Distribution Channel	Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies

Anti-Obesity Medication Market Report Highlights:

• The anti-obesity medication market size is expected to grow at USD 105.3 billion by 2035.
• The target market was worth USD 8.5 billion in 2024.
• Target market is expanding at a CAGR of 31.8%.
• North America held the largest share of the market in 2024.
• Asia Pacific is projected to be the fastest-growing market in the coming years.
• On the basis of drug type, the market is being dominated by the prescription drugs segment.
• Based on mechanism of action, the centrally acting drugs holds the largest anti-obesity medication market share.
• Distribution channel, the hospital pharmacies segment is leading the market.

Anti-Obesity Medication Market Dynamics:

Growth Factor	Challenge Factor	Market Trend
Surging Obesity Cases	Serious Anti-Obesity Medication Side Effects	New Ant-Obesity Drug Development

Key Highlights:

• In November 2024, a recent study published in the JAMA Network Open, researchers evaluated changes in alcohol use among individuals enrolled in a telehealth weight management program after initiating antiobesity medication (AOM). AOMs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are effective for achieving significant weight loss. Notably, GLP-1 RAs have also been linked to reduced incidence and recurrence of alcohol use disorder, thus suggesting potential dual benefits of these medications.
•  In November 2024, The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment. The new rule, which was proposed by the administration, would dramatically expand access to anti-obesity medications, such as Ozempic and Wegovy, from Novo Nordisk, and Mounjaro and Zepbound, from Eli Lilly.

Anti-Obesity Medication Market Report Analysis:

Drugs Approved for Long Term Treatment of Obesity-

Drug & Class	Ideal Candidates	Side Effects	Contraindications
Lisdexamfetamine (amphetamine prodrug)	Patients with attention deficit hyperactivity disorder	Insomnia, irritability, anxiety, dry mouth, increased heart rate and blood pressure. Controlled substance with theoretical potential for abuse and dependence.	None
Phentermine (sympathomimetic amine)	N/A	Headaches, increased blood pressure and heart rate, irritability, insomnia, constipation, diarrhea, impotence, dizziness. Controlled substance with theoretical potential for abuse and dependence. Serious but rare: pulmonary hypertension, valvular disease.	Uncontrolled anxiety and hypertension, cardiovascular disease, hyperparathyroidism, glaucoma, and history of drug dependence.
Topiramate (GABA receptor modulator)	Patients with chronic migraines	Insomnia, xerostomia, constipation, paresthesia, dizziness, anxiety, depression, drowsiness, language and memory impairments. Very rare: seizures with rapid discontinuation.	Hyperthyroidism, glaucoma.
Metformin (biguanide)	Patients with diabetes and prediabetes	Diarrhea, nausea, abdominal pain. Serious but rare: lactic acidosis.	Severe chronic kidney disease.
Pramlintide (amylin analogue)	Patients with type 1 or type 2 diabetes	Hypoglycemia, headaches, nausea, vomiting.	Gastro paresis and hypoglycemic unawareness.
SGLT-2 inhibitors	Patients with type 2 diabetes, hypertension, heart failure, cardiovascular disease, diabetic kidney disease	Genitourinary infections, hypovolemia, increased low-density lipoprotein cholesterol, and hyperkalemia. Serious but rare: diabetic ketoacidosis, bone fractures, amputations, Fournier gangrene.	Severe chronic kidney disease and ketogenic diet (concern for euglycemic ketoacidosis).

Browse ∼40 market data tables and ∼38 figures through ∼183 slides and in-depth TOC on “Anti-Obesity Medication Market Size, Share, By Drug Type, Mechanism of Action, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035”

For more insights into Anti-Obesity Medication Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/anti-obesity-medication-market-5717

Anti-Obesity Medication Market Competitive Landscape:

The key players in the anti-obesity medication market are Novo Nordisk A/S, ELI LILLY AND COMPANY, GSK plc., Currax Pharmaceuticals LLC, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech, Inc., CHEPLAPHARM ARZNEIMITTEL GMBH, Gelesis, VIVUS LLC, Rhythm Pharmaceuticals, Inc., Lupin Ltd., Zydus Group, and BIOCON.

Company Name	ELI LILLY AND COMPANY
Headquarter	Indiana, U.S.
CEO	David A. Ricks
Employee Count (2024)	46,240 Employees